eISSN: 1897-4295
ISSN: 1734-9338
Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2021
vol. 17
 
Share:
Share:
abstract:
Short communication

Transcatheter transseptal mitral valve implantation with Edwards SAPIEN 3: the first experience of a single center

Paweł Kralisz
1
,
Marek Frank
2
,
Bożena Sobkowicz
3
,
Slawomir Dobrzycki
1
,
Tomasz Hirnle
2

1.
Department of Invasive Cardiology, University Hospital, Bialystok, Poland
2.
Department of Cardiosurgery, University Hospital, Bialystok, Poland
3.
Department of Cardiology, University Hospital, Bialystok, Poland
Adv Interv Cardiol 2021; 17, 1 (63): 105–108
Online publish date: 2021/03/27
View full text Get citation
 
In recent years, there has been a clear trend towards increased mitral bioprosthetic valve surgery in comparison to mechanical prostheses [1]. According to the ESC Guidelines mitral bioprostheses are recommended for patients > 70 years old or those with a life expectancy lower than the presumed durability of the bioprosthesis (class IIa/C). Importantly, the guidelines also recognize the prominence of quality of life after cardiosurgery and focus on patients’ preferences (class Ic), especially if long-term anticoagulation is nonoptimal (class Ic) [2]. Structural deterioration of mitral bioprostheses (structural valve deterioration – SVD) is the main limitation for their use. The average lifespan of a bioprosthetic valve is estimated at 16 years and the reoperation due to SVD affects as many as 75% of patients after a 20-year follow-up [3, 4]. Reoperation is usually associated with high risk of complications and mortality [5, 6].
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.